Kaynak: Zacks Investment Research Haber Ajansı
1 ay önce•
Hisse Senedi Orta Önem
ADMA Q2 Earnings Meet, Revenues Miss on Bivigam Weakness

ADMA Q2 Earnings Meet, Revenues Miss on Bivigam Weakness

ADMA Biologics matches earnings estimates, misses on revenues and maintains its 2026 outlook as strong Asceniv growth offsets continued pressure on Bivigam.
İlgili Semboller 1
ADMA ADMA
Kaynak: Zacks Investment Research
Kaynağı Ziyaret Et
0 0 0
Yorum Yap
Yorumlar
0
Henüz yorum yok
Bu habere ilk yorum yapan kişi olun.